Non-ionic surfactants self-assemble into vesicular systems called niosomes in aqueous solutions with the help of physical agitation or high temperatures. Nonionic surfactants, as opposed to phospholipids, are used as the constituents of the membrane, which circumvents many of the drawbacks of liposomes, including inadequate chemical stability, phospholipids' oxidation susceptibility, high production costs, and the need for particular handling and storage conditions. Because of their unique shape, which consists of an inner aqueous compartment encircled by a hydrophobic membrane, hydrophilic and hydrophobic drug molecules can be incorporated and delivered, respectively. In addition, niosomes are biocompatible, biodegradable, nontoxic, and osmotically active. Niosomes were first proposed as a workable solution for the cosmetics industry in the 1970s, and in the 1980s, L'Oreal filed for patents on the ingredient. Their advantageous qualities establish theIn recent times, there has been a dramatic shift in the treatment of infectious diseases and vaccination strategies. Along with the creation of many biologicals targeted at specific diseases, biotechnology and genetic engineering have also brought attention to the effective delivery of these biologicals. Niosomes, which are vesicles made of non-ionic surfactants and less expensive than liposomes, are biodegradable, harmless, stable, and less expensive than liposomes. This article summarizes various studies that have examined the effectiveness of using niosomes for various diseases.